Solazyme's Parity-Cost, Algae-Based Biodiesel on Sale to Public
Jim Lane $27 per gallon? $15 per gallon? Fooey! Try algae-based fuels at “the same cost as regular diesel.” Month-long pilot program kicks off in the San Francisco Bay Area. In California, Propel Fuels and Solazyme (SZYM) are bringing algae-derived fuel to retail pumps for what we believe to be the first time in history. The two leading renewable fuel brands have come together to offer Solazyme’s algae-based SoladieselBD to drivers through Propel’s Bay Area network of retail renewable fuel locations. The month-long pilot program provi
http://www.altenergystocks.com/archives/2012/11/solazymes_paritycost_algaebased_biodiesel_on_sale_to_public_1.html 2012-11-14 08:34:19 PST

Aastrom Biosciences' CEO Discusses Q3 2012 Results - Earnings Call Transcript
Aastrom Biosciences, Inc. (ASTM) Q3 2012 Earnings Call November 8, 2012 04:30 p.m. ET Executives Brian Gibson – VP, Finance Timothy Mayleben – President and CEO Daniel Orlando – Chief Commercial Officer Analysts Steve Brozak – WBB Securities Megan Down – McNicoll, Lewis, & Vlak Boris Peacker – OppenheimerJason Napodano - Zacks Presentation Operator Ladies and gentlemen, thank you for standing by. Welcome to Aastrom Biosciences Third Quarter 2012 Conference Call. At this time, all participants are in a listen-only
http://seekingalpha.com/article/994711-aastrom-biosciences-ceo-discusses-q3-2012-results-earnings-call-transcript?source=feed 2012-11-09 09:40:06 PST

Will Shares Of Aastrom Really Triple From Today's Levels Within A Year?
By M.E. Garza: Late last week, the Maxim Group initiated coverage on shares of Aastrom Biosciences (ASTM) with a Buy Rating and a 12-month price target of $6.Shares of the company had been falling along with the rest of the markets, but now that Aastrom is enrolling patients in a pivotal Phase III trial for critical limb ischemia analysts at the firm feel that shares should head back up based on a high probability of success given the prior data sets and powering of the current program.In a note to clients, Maxim's analysts point out that crit
http://seekingalpha.com/article/636381-will-shares-of-aastrom-really-triple-from-today-s-levels-within-a-year?source=feed 2012-06-04 15:22:51 PST

Renewable Energy Stocks Trading Alert; BIOX (BX.TO) Up Over 38%
Point Roberts WA- Aug. 10, 2011 (Investorideas.com renewable energy/green newswire) Investorideas.com, a leader in cleantech investor research, issues a trading alert for BIOX CORPORATION (Toronto: BX.TO), a renewable energy company that designs, builds, owns and operates biodiesel production facilities.  The stock is trading up over 38% on light volume. About BIOX Corporation BIOX is a renewable energy company that designs, builds, owns and operates biodiesel production facilities. BIOX currently owns and operates a biodiesel
http://cleanenergynews.blogspot.com/2011/08/renewable-energy-stocks-trading-alert.html 2011-08-10 13:18:44 PST

Athersys: Grossly Undervalued Given Its Potential
Wall Street Titan submits:Investors in the stem cell sector (GERN, OSIR, STEM, CUR, ATHX, ASTM, MEOBF.PK, PSTI, NBS, BHRT) should have at least a basic understanding as to some of the various approaches used by competing companies. For example, Cytori Therapeutics (CYTX), a company I have followed closely, takes the “
http://seekingalpha.com/article/266853-athersys-grossly-undervalued-given-its-potential?source=feed 2011-05-01 04:38:35 PST

5 Stocks Under $10 With New Insider Buying
Rougemont submits: All of the following companies have recently reported insider buying. The fact that insiders are buying these names could be a good sign that there is significant upside potential in these shares. I have provided links for each stock which verifies the insider buying filed with the SEC below. Here are the five stocks:Aastrom Biosciences, Inc. (ASTM) is trading around $2.30. Aastrom is a biotechnology company, based in Michigan. The 50-day moving average is $2.43 and the 200-day moving average is $2.10. These shares have
http://seekingalpha.com/article/261335-5-stocks-under-10-with-new-insider-buying?source=feed 2011-04-01 08:28:20 PST

Good News for Aastrom Bio:; IMPACT-DCM Trials Show Proof-of-Concept
Jason Napodano submits: This morning at the Sixth International Conference on Cell Therapy for Cardiovascular Disease, Aastrom Bio (ASTM) presented interim data from the first 40 patients at 6-months from the company’s IMPACT-DCM program. As a reminder, the Phase II IMPACT-DCM (surgical) program looked at the safety and efficacy of direct injection of Tissue Repair Cells (TRCs) into damaged areas of the myocardium. The trial was a prospective, open-label program with a crossover extension study for the control patients. Baseline patient
http://seekingalpha.com/article/247707-good-news-for-aastrom-bio-impact-dcm-trials-show-proof-of-concept?source=feed 2011-01-20 19:55:55 PST

Bear Radar
Style Underperformer:Mid-Cap Growth (+.31%)Sector Underperformers:1) Coal -3.85% 2) Gold -1.70% 3) Steel -.82%Stocks Falling on Unusual Volume:AIG, ANR, EVN, SLXP, ACOR, SLW, PZE, IPGP, CSIQ, CSTR, INSU, SODA, CCME, HMIN, CENX and ABVStocks With Unusual Put Option Activity:1) SLM 2) SCCO 3) WFR 4) CVS 5) BBDStocks With Most Negative News Mentions:1) SO 2) ASTM 3) JASO 4) HNT 5) NVT
http://hedgefundmgr.blogspot.com/2011/01/bear-radar_14.html 2011-01-14 13:05:00 PST

Aastrom Biosciences Headed for a Transformative Year
M.E. Garza submits: By Patrick CrutcherIn many ways, 2011 should be a transformative year for Aastrom Biosciences (ASTM). To start off the year, they will be presenting Phase 2 Surgical-DCM six-month results sometime this month, followed up by several (3-5) other key catalysts that investors should be looking for in 2011. We think they have the potential to become the clear leader in stem cells for cardiovascular diseases.Complete Story »
http://seekingalpha.com/article/245744-aastrom-biosciences-headed-for-a-transformative-year?source=feed 2011-01-10 11:49:27 PST

Aastrom Biosciences' Uptrend Fueled by More Than Just Market Momentum
Edward Stevenson submits:A bullish crossover of the MACD indicator suggests the beginning of a new uptrend for Aastrom Biosciences, Inc. (ASTM). On Tuesday volume jumped to nearly three times the 3-month average without any news from the company. Volume, often interpreted as the lifeblood of a chart, measures strength behind price movement in technical analysis. With the price breaking above its 50 day moving average line (blue), Tuesday's share volume confirms the 'technical breakout' - a move through or above a significant level of resistance
http://seekingalpha.com/article/243971-aastrom-biosciences-uptrend-fueled-by-more-than-just-market-momentum?source=feed 2010-12-29 04:55:37 PST